Pacira BioSciences, Inc. (PCRX) will present new findings from its Phase 1 clinical trial of gene therapy candidate PCRX-201 in osteoarthritis of the knee at the 28th Annual Meeting of the American Society of Gene and Cell Therapy or ASGCT on Thursday, May 15, 2025.
The presentation will focus on the clinical immunogenicity of the therapy and its implications for optimizing dosing strategy in knee osteoarthritis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com